Background: Accumulating evidence indicates that eotaxin is the primary mediator of tissue eosinophilia. In the present study, we analyzed the mechanisms of eotaxin generation by Th1-/Th2-derived cytokines in vitro. Methods: Human dermal fibroblasts, human umbilical vein endothelial cells and A549 human bronchial epithelial cell line cells were stimulated with TNF-α, IL-4, IFN-γ or TNF-α in combination with IL-4 or IFN-γ and the amount of eotaxin production was analyzed. Results: Fibroblasts produced nanogram/milliliter quantities of eotaxin. Proinflammatory cytokine TNF-α and Th2-type cytokine IL-4 each induced eotaxin production, and combination of them caused a marked synergistic increase in that production. On the other hand, Th1-type cytokine IFN-γ inhibited eotaxin generation at the protein/mRNA levels. Conclusion: The Th2-derived cytokine upregulated while the Th1-derived cytokine inhibited eotaxin production by fibroblasts. In view of the Th1/Th2 paradigm, these results indicate that (1) eotaxin regulates eosinophil accumulation in the Th2-dominant state such as allergic disease, and (2) direct suppression of eotaxin production by IFN-γ is one of the major mechanisms by which IFN-γ suppresses eosinophilic inflammation.

Keywords:
Eotaxin, Fibroblast, Allergy, Eosinophil, TNF-α, IL-4, IFN-=γ, Th1/Th2 paradigm
1.
Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, Newman W, Gerard C, Mackay CR: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183:2437–2448.
2.
Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD, Mackay CR: Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178–184.
3.
Yamada H, Hirai K, Miyamasu M, Iikura M, Misaki Y, Shoji S, Takaishi T, Kasahara T, Morita Y, Ito K: Eotaxin is a potent chemotaxin for human basophils. Biochem Biophys Res Commun 1997;231:365–368.
4.
Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA: High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997;100:1137–1143.
5.
Rothenberg ME, Luster AD, Leder P: Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin-4-induced tumor suppression. Proc Natl Acad Sci USA 1995;92:8960–8964.
6.
Mochizuki M, Bartels J, Mallet AI, Christophers E, Schroder JM: IL-4 induces eotaxin: A possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160:60–68.
7.
Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169–1174.
8.
Palframan RT, Collins PD, Williams TJ, Rankin SM: Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91:2240–2248.
9.
Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepeda EA, Allakhverdi Z, Ghaffar O, Rothenberg ME, Luster AD, Hamid Q: Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593–4601.
10.
Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449–456.
11.
Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, Drazen JM, Luster AD: Expression of eotaxin by human lung epithelial cells: Induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767–1773.
12.
Miyamasu M, Nakajima T, Misaki Y, Izumi S, Tsuno N, Ohta K, Kasahara T, Yamamoto K, Morita Y, Hirai K: Dermal fibroblasts represent a potent major source of human eotaxin: In vitro production and cytokine-mediated regulation. Cytokine 1999;Oct;11:751–758.
13.
Nakajima T, Yamada H, Iikura M, Miyamasu M, Izumi S, Shida H, Ohta K, Imai T, Yoshie O, Mochizuki M, Schroder JM, Morita Y, Yamamoto K, Hirai K: Intracellular localization and release of eotaxin from normal eosinophils. FEBS Lett 1998;434:226–230.
14.
Miyamasu M, Hirai K, Takahashi Y, Iida M, Yamaguchi M, Koshino T, Takaishi T, Morita Y, Ohta K, Kasahara T, Ito K: Chemotactic agonists induce cytokine generation in eosinophils. J Immunol 1995;154:1339–1349.
15.
Izumi S, Hirai K, Miyamasu M, Takahashi Y, Misaki Y, Takaishi T, Morita Y, Matsushima K, Ida N, Nakamura H, Kasahara T, Ito K: Expression and regulation of monocyte chemoattractant protein-1 by human eosinophils. Eur J Immunol 1997;27:816–824.
16.
Miyamasu M, Yamaguchi M, Nakajima T, Misaki Y, Morita Y, Matsushima K, Yamamoto K, Hirai K: Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin synthesis in vitro. Int Immunol 1999;11:1001–1004.
17.
Bartels J, Schluter C, Richter E, Noso N, Kulke R, Christophers E, Schroder JM: Human dermal fibroblasts express eotaxin: Molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem Biophys Res Commun 1996;225:1045–1051.
18.
Iwamoto I, Nakajima H, Endo H, Yoshida S: Interferon gamma regulates antigen-induced eosinophil recruitment into the mouse airways by inhibiting the infiltration of CD4+ T cells. J Exp Med 1993;177:573–576.
19.
Kung TT, Stelts D, Zurcher JA, Watnick AS, Jones H, Mauser PJ, Fernandez X, Umland S, Kreutner W, Chapman RW, Egan RW: Mechanisms of allergic pulmonary eosinophilia in the mouse. J Allergy Clin Immunol 1994;94:1217–1224.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.